Pfizer's Set to Make $131 Billion in COVID Sales in 2 Years. Is the Stock a Buy? | The Motley Fool
Despite some risks, there's a pretty good case to be made for the big pharma stock.
www.fool.com
Just in time:
Pfizer set to lose ‘billions of dollars’ as drug patents expire
Pfizer set to lose ‘billions of dollars’ as drug patents expire
Pharma giant reports worse-than-expected fourth-quarter results on weak Viagra sales
www.irishtimes.com
You don't have permission to view the spoiler content.
Log in or register now.